NCT06321055View on ClinicalTrials.gov

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

CompletedOBSERVATIONAL
Enrollment

136

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Advanced Gastrointestinal Stromal Tumor
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

Retrospective analysis.

Trial Locations (1)

07981

Bayer, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06321055 - An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States | Biotech Hunter | Biotech Hunter